[1] Zhang Y, Dai Y, Li R,et al.The role of E-cadherin in Helicobacter pylori-related gastric diseases[J]. Current Drug Metabolism, 2019, 20(1): 23-28.
[2] 张万岱,胡伏莲,萧树东,等.中国自然人群幽门螺杆菌感染的流行病学调查[J].现代消化及介入诊疗,2010,15(5):265-270.
[3] 谢川, 吕农华. 中国幽门螺杆菌感染的现状[J]. 疾病监测,2018,33(4):272-275.
[4] 陈梅红,严谨,党旖旎,等.幽门螺杆菌对抗菌药物耐药的研究进展[J].胃肠病学,2019,24(2):115-118.
[5] Hunt RH, Xiao SD, Megraud F, et al.Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline[J]. J Gastrointestin Liver Dis, 2011, 20(3): 299-304.
[6] Rodrigues MN, Queiroz DM, Bezerra Filho JG, et al.Prevalence of Helicobacter pylori infection in children from an urban community in north-east Brazil and risk factors for infection[J]. Eur J Gastroenterol Hepatol, 2004, 16(2): 201-205.
[7] Parkin DM.The global health burden of infection-associated cancers in the year 2002[J]. Int J Cancer, 2006, 118(12): 3030-3044.
[8] Parente JM, da Silva BB, Palha-Dias MP, et al. Helicobacter pylori infection in children of low and high socioeconomic status in northeastern Brazil[J]. Am J Trop Med Hyg, 2006, 75(3): 509-512.
[9] Ben MK, Fendri C, Battikh H, et al.Multiple and mixed Helicobacter pylori infections: Comparison of two epidemiological situations in Tunisia and France[J]. Infect Genet Evol, 2016, 37: 43-48.
[10] Lim SH, Kwon JW, Kim N, et al.Prevalence and risk factors of Helicobacter pylori infection in Korea: Nationwide multicenter study over 13 years[J]. BMC Gastroenterology, 2013, 13(1):104-113.
[11] 孙慧响, 邹珍, 黄跃平等. 上海市某郊区社区人群幽门螺杆菌感染的流行病学调查[J]. 上海预防医学, 2018, 30(4): 295-298.
[12] 陈利, 贾雪梅, 王书学. 北京密云地区体检人群幽门螺杆菌感染现状及危险因素分析[J]. 中国综合临床, 2017, 33(10): 891-894.
[13] 张国珍,赖育清,黄少琼,等.消化性溃疡并Hp感染的发病状况与影响因素分析[J].现代诊断与治疗,2016,27(6):991-993.
[14] 林昌平. 浙江苍南地区幽门螺杆菌流行趋势及耐药现状研究[J]. 中华消化内镜杂志, 2014(31):340-342.
[15] Irigrácin LDB, Maria FCC, Janilson DSC, et al.Risk factors of Helicobacter pylori infection in an urban community in Northeast Brazil and the relationship between the infection and gastric diseases[J]. Revista Da Sociedade Brasileira De Medicina Tropical, 2018, 51(2):183-189 .
[16] Gasbarrini A, Anti M, Franceschi F, et al.Prevalence of and risk factors for Helicobacter pylori infection among healthcare workers at a teaching hospital in Rome: The catholic university epidemiological study[J]. Eur J Gastroenterol Hepatol, 2001, 13(2):185-189.
[17] Wong WM,GU Q,Wang WH,et al.Effects of primary metronidazole and clarithromycin resistance to Helicobacter pylori On omeprazole,metronidazole,and clarithromycin triple-therapy regimen in a region with high rates of metronidazole resistance[J].Clin Infect Dis,2003,37(7):882-889.
[18] Sun QJ, Liang X, Zheng Q, et al.Resistance of Helicobacter pylori to antibiotics from 2000 to 2009 in Shanghai[J]. World J Gastroenterol, 2010, 16:5118-5121.
[19] 迟锦瑜,杨丽花,王辉.大理市基层医疗机构抗菌药物使用情况及细菌耐药监测分析[J].华南预防医学,2019,45(5):449-452.
[20] De Francesco V, Giorgio F, Hassan C, et al.Worldwide H. pylori antibiotic resistance: a systematic review[J]. J Gastrointestin Liver Dis, 2010, 19:409-414.
[21] Megraud F.Antibiotic resistance in Helicobacter pylori infection[J].Br Med Bull, 1998, 54:207-216.
[22] Fock KM, Katelaris P, Sugano K, et al.Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection[J]. J Gastroenterol Hepatol, 2009, 24:1587-1600. |
